Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation.

ABSTRACT:

Objective

To assess the value of using SARS-CoV-2 specific antibody testing to prioritize the vaccination of susceptible individuals as part of a COVID-19 vaccine distribution plan when vaccine supply is limited.

Methods

An extended susceptible-infected-recovered (SIR) compartmental model was used to simulate COVID-19 spread when considering diagnosis, isolation, and vaccination of a cohort of 1 million individuals. The scenarios modeled represented 4 pandemic severity scenarios and various times when the vaccine becomes available during the pandemic. Eligible individuals have a probability p of receiving antibody testing prior to vaccination (p = 0, 0.25, 0.5, 0.75, and 1). The vaccine was modeled as a single dose vaccine with 90% and 70% efficacy. The value of serology tes

SUBMITTER: Fujimoto AB 

PROVIDER: S-EPMC8233959 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature